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ABSTRACT
Objective: To describe the clinical spectrum, diagnostic evaluation, current management, and
neurologic outcome of pediatric antibody-associated inflammatory brain diseases (AB-associated
IBrainD).
Methods: We performed a single-center retrospective cohort study of consecutive patients aged
#18 years diagnosed with an AB-associated IBrainD at The Hospital for Sick Children, Toronto,
Ontario, Canada, between January 2005 and June 2013. Standardized clinical data, laboratory
test results, neuroimaging features, and treatment regimens were captured.
Results: Of 169 children (93 female, 55%) diagnosed with an IBrainD, 16 (10%) had an AB-
associated IBrainD. Median age at presentation was 13.3 years (range 3.1–17.9); 11 (69%)
were female. Nine patients (56%) had anti–NMDA receptor encephalitis, 4 (25%) had
aquaporin-4 autoimmunity, 2 (13%) had Hashimoto encephalitis, and 1 (6%) had anti–glutamic
acid decarboxylase 65 (GAD65) encephalitis. The key presenting features in children with anti–
NMDA receptor encephalitis, Hashimoto encephalopathy, and anti-GAD65 encephalitis included
encephalopathy, behavioral symptoms, and seizures; patients with aquaporin-4 autoimmunity
showed characteristic focal neurologic deficits. Six patients (38%) required intensive care unit
admission at presentation. Median time from symptom onset to diagnosis was 55 days (range
6–358). All but 1 patient received immunosuppressive therapy. One child with anti–NMDA recep-
tor encephalitis died due to multiorgan failure. At last follow-up, after a median follow-up time of
1.7 years (range 0.8–3.7), 27% of the children had function-limiting neurologic sequelae.
Conclusions: Children with AB-associated IBrainD represent an increasing subgroup
among IBrainD; 1 in 4 children has function-limiting residual neurologic deficits. Awareness of
the different clinical patterns is important in order to facilitate timely diagnosis and initiate immu-
nosuppressive treatment. Neurol Neuroimmunol Neuroinflamm 2015;2:e92; doi: 10.1212/
NXI.0000000000000092
GLOSSARY
AB-associated IBrainD 5 antibody-associated inflammatory brain diseases; AQP4 5 aquaporin-4; CRP 5 C-reactive
protein; ESR5 erythrocyte sedimentation rate; FLAIR5 fluid-attenuated inversion recovery;GAD655 glutamic acid decar-
boxylase 65; IBrainD 5 inflammatory brain diseases; ICU 5 intensive care unit; IgG 5 immunoglobulin G; LETM 5 longitu-
dinally extensive transverse myelitis; NMO 5 neuromyelitis optica; ON 5 optic neuritis; PSOM 5 Pediatric Stroke Outcome
Measure; TPO 5 thyroperoxidase.
Inflammatory brain diseases (IBrainD) affect previously healthy children and can cause life-
threatening neurologic deficits. The disease spectrum encompasses several distinct entities,
including vasculitides, granulomatous conditions, and T cell– and antibody-associated dis-
eases.1–5 In antibody-associated inflammatory brain diseases (AB-associated IBrainD), activated
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B cells produce specific antibodies against dif-
ferent structures in the CNS, including cell
surfaces, synaptic proteins, and channels.3,6–9
Despite the growing number of recognized
conditions and the achievements related to tar-
geted treatment, the clinical heterogeneity
within this group often leads to a delay in diag-
nosis and hence a high risk of poor outcomes.
Therefore, the objectives of this study were
to (1) describe the clinical phenotype of dis-
tinct childhood AB-associated IBrainD, (2)
review the diagnostic evaluation and current
management, and (3) assess the neurologic
outcome at the last follow-up.
METHODS Population and setting. This was a single-
center retrospective cohort study of consecutive patients
younger than 18 years of age who were seen at The Hospital
for Sick Children from January 1, 2005 to June 30, 2013, and
diagnosed with an IBrainD. Included were patients with a
confirmatory antibody detected in serum and/or CSF (see
testing panel later in this section) in the context of a newly
acquired neurologic and/or psychiatric deficit not otherwise
explained with a follow-up period of at least 6 months.10
Excluded were children with non–AB-associated IBrainD or with
IBrainD that were presumed to be AB-associated but with no
confirmatory test. All children diagnosed with IBrainD were
followed in the IBrainD and CNS vasculitis clinics at The
Hospital for Sick Children. Standardized clinical data, laboratory
test results, neuroimaging features, and outcome information were
prospectively collected and captured in a designated research
database (BrainWorks, the international Web-based password-
protected prospective cohort of children with IBrainD). Patients
were identified from the database and data were supplemented with
additional information found in the electronic patient charts.
Standard protocol approvals, registrations, and patient
consents. Written informed consent was obtained from all study
participants (parents/legal guardians). The study was approved by
the research ethics board of The Hospital for Sick Children (REB
1000014279).
Clinical data. Information of interest included sex, age at diag-
nosis, duration of symptoms before diagnosis, initial clinical pre-
sentation (mental status, level of consciousness, neurologic
examination, seizures), severity of disease at presentation (ward
vs intensive care unit [ICU] admission), and length of acute inpa-
tient management (defined as the length of time between initial
presentation and discharge from acute care facility). The detailed
definition of clinical signs and symptoms is given in table e-1 at
Neurology.org/nn.
Investigations. All study participants underwent a standardized
test battery unless there were contraindications for certain tests to
be performed. The general laboratory workup included white blood
cell count, C-reactive protein (CRP), erythrocyte sedimentation
rate (ESR), albumin, immunoglobulin G (IgG), von Willebrand
factor antigen, protein C/S, factor V Leiden, homocysteine, lupus
anticoagulants, methylenetetrahydrofolate reductase, C3, C4, ferri-
tin, lipid profile, antinuclear antibodies, double-stranded DNA,
anti-neutrophil cytoplasmic autoantibody, rheumatoid factor,
anti-cardiolipin antibodies, anti-Ro antibodies, anti-La antibodies,
thyroperoxidase (TPO) antibodies, and CSF analysis (cell count,
protein, oligoclonal bands). Serologies included varicella-zoster
virus, hepatitis B and C, enterovirus, Mycoplasma pneumoniae,
cytomegalovirus, Epstein-Barr virus, Bartonella henselae,
Treponema pallidum, and Borrelia burgdorferi.
A malignancy workup (abdominal ultrasound and/or MRI)
was performed if indicated.
Antibody testing was performed prior to treatment initiation
in all patients. Paired serum/CSF samples were used for anti–
NMDA receptor and anti–glutamic acid decarboxylase 65
(GAD65) antibody testing, as previously described.11 Testing
included other cell surface or synaptic receptors (AMPA receptor,
GABAA receptor, GABAB receptor, GlyR, mGluR5R, LGI1,
Caspr2, DPPX). Anti-TPO antibodies were tested in serum at
The Hospital for Sick Children; a titer of .35 IU/L was consid-
ered positive. Neuromyelitis optica (NMO)-IgG was tested in
serum and/or CSF using ELISA. All NMO-IgG testing was per-
formed at the same institution (NMO testing reference center).
MRI of the brain and/or spine at presentation was reviewed
by 2 independent investigators (S.B., S.M.B.). Lesion location
(supratentorial/infratentorial/spinal cord) and enhancement were
recorded. Spinal cord lesions of $3 segments were identified as
longitudinally extensive transverse myelitis (LETM).
Immunosuppressive treatment included the institutional proto-
col (see figures e-1 and e-2, depending on disease severity at onset)
or modified regimens. Symptomatic treatment included manage-
ment of seizure control and psychotropic agents as indicated.
Outcome. Primary outcome was the neurologic functioning at
last clinical encounter, defined by the Pediatric Stroke Outcome
Measure (PSOM). The PSOM is a standardized and validated
pediatric outcome measure routinely used in BrainWorks and
in the IBrainD clinics. The PSOM categorizes outcome as either
good (normal function or mild deficit with no impact on func-
tion) or bad (any deficit affecting function).12
Secondary outcomes included survival, school participation,
support at school (defined as presence of an individualized educa-
tion program or other support), and assessment of residual
seizures.
Analysis. Children were assigned to distinct subgroups based on
their presenting antibody. For each subgroup, clinical presenta-
tion, inflammatory markers, neuroimaging findings, and out-
come measures were captured using descriptive statistics.
RESULTS A total of 169 children were diagnosed
with an IBrainD. Sex distribution was balanced (93
female, 55%); the mean age at diagnosis was 9.9 years
(SD 4.8 years). Figure 1 illustrates the distribution of
the different diagnoses encountered in this cohort.
The largest group was formed by patients with pri-
mary (n 5 67; 40%) and secondary (n 5 18; 10%)
vasculitis and CNS vasculopathies (n 5 24; 14%),
presenting respectively with acute ischemic stroke or
nonischemic focal neurologic deficits alongside an
abnormal brain MRI in the majority of the cases.
The group of other IBrainD (n 5 44; 26%) is het-
erogeneous, including patients with Rasmussen
encephalitis or granulomatous diseases presenting
with focal seizures/epilepsia partialis continua and
cranial neuropathies with or without raised intracra-
nial pressure, respectively. A total of 16 children
(10%) were identified as having an AB-associated
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IBrainD; an outline of their baseline characteristics is
given in table 1. Children with AB-associated
IBrainD showed a female preponderance (11 girls,
69%). The largest subgroup (9 patients, 56%)
consisted of patients with anti–NMDA receptor
encephalitis and included the youngest patients of
all the subgroups. Overall time from symptom
onset to diagnosis varied from 6 days to 12 months,
with a median duration of 55 days. Patients with the
less common conditions, such as anti-GAD65
encephalitis, demonstrated the longest time to
diagnosis. Overall, the median follow-up time was
1.7 years (range 0.8–3.7 years).
Antibody testing. Of the patients diagnosed with anti–
NMDA receptor encephalitis and anti-GAD65
encephalitis, the majority (9 children, 90%) had
positive antibodies in both serum and CSF. Only
1 child with anti–NMDA receptor encephalitis
showed positive antibody testing solely in the CSF.
All patients diagnosed with aquaporin-4 (AQP4)
autoimmunity showed positive NMO-IgG in the
serum, with the exception of one who had repeatedly
negative NMO-IgG in serum but a positive test in the
CSF. The 2 patients with Hashimoto encephalitis had
elevated anti-TPO titers in the serum alongside
negative testing of other neuronal autoantibodies.
Anti–NMDA receptor encephalitis. Nine children (6
female, 67%) were diagnosed with anti–NMDA
receptor encephalitis at a median age of 10.8 years
(range 3.1–17.9 years). All 9 children presented with
encephalopathy and behavioral changes. The latter
consisted of severe agitation, irritability, and aggres-
sion toward family and medical staff. The majority
also showed various movement disorders (dystonic
posturing, dyskinesias, and choreatic movements)
and seizures. Hallucinations (visual and auditory)
were reported in almost half of the patients (4 chil-
dren, 44%).
Malignancy and systemic inflammatory rheuma-
tologic workups were negative in all patients. MRI
studies were also normal in the majority of patients;
only 1 child whose initial MRI was performed after
6 days of encephalopathy had abnormal findings con-
sisting of brain edema with effacement of sulci and
decreased size of the ventricles (table 2).
ICU admission was required in 4 patients due to
uncontrollable agitation (2 children), partial status
epilepticus (1 child), and multiorgan failure (1 child).
Immunosuppressive medication was started in all pa-
tients; 6 were treated according to the institutional
protocol (figures e-1 and e-2) and 3 were treated with
a modified immunosuppression regimen without rit-
uximab. All 6 patients presenting with seizures were
treated with antiepileptic medication; psychotropic
agents were necessary in 7 patients. One child died
during the course of the treatment due to acute respi-
ratory distress syndrome and multiorgan failure. At
Table 1 Demographics, diagnostic delay, acute management, and follow-up of children diagnosed with antibody-associated inflammatory
brain diseases
Antibody- associated
IBrainD (n 5 16)
Anti–NMDA receptor
encephalitis (n 5 9)
Aquaporin-4
autoimmunity
(n 5 4)
Hashimoto
encephalitis
(n 5 2)
Anti-GAD65
encephalitis
(n 5 1)
Females, n (%) 11 (69) 6 (67) 3 (75) 2 (100) 0 (0)
Age at diagnosis, y, median (range) 13.3 (3.1–17.9) 10.8 (3.1–17.9) 16.6 (11.8–17.1) 12.1 (11.2–12.9) 15.5 (—)
Time from symptom onset to
diagnosis, d, median (range)
55 (6–358) 47 (10–70) 67 (13–122) 90 (6–173) 358 (—)
Intensive care unit admission
at onset, n (%)
6 (38) 4 (44) 1 (25) 1 (50) 0 (0)
Length of acute management,
d, median (range)
52 (5–182) 63 (32–182) 35 (13–75) 19 (5–33) 47 (—)
Duration of follow-up, y, median
(range)
1.7 (0.8–3.7) 1.8 (0.8–3.7) 1.5 (1.0–1.8) 1.9 (1.5–2.2) 2.4 (—)
Abbreviations: IBrainD 5 inflammatory brain diseases; GAD65 5 glutamic acid decarboxylase 65.
Figure 1 Frequency of pediatric inflammatory brain diseases (IBrainD) by
diagnosis
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last clinical encounter after a median follow-up time
of 1.8 years (range 0.8–3.7 years), the majority of
the surviving children had a good outcome. One child
was in a rehabilitation facility due to mild motor and
severe behavioral issues. None of the children re-
ported ongoing seizures (table 3).
AQP4 autoimmunity. Four children (3 female, 75%)
were diagnosed with AQP4 autoimmunity at a
median age of 16.6 years (range 11.8–17.1 years).
All 4 children presented with characteristic focal neu-
rologic signs and symptoms, including intractable
hiccups and/or vomiting (2 children), optic neuritis
Table 2 Presenting clinical, laboratory, and neuroimaging features of children diagnosed with antibody-associated inflammatory brain
diseases
Antibody-
associated IBrainD
(n 5 16)
Anti–NMDA receptor
encephalitis
(n 5 9)
Aquaporin-4
autoimmunity
(n 5 4)
Hashimoto
encephalitis
(n 5 2)
Anti-GAD65
encephalitis
(n 5 1)
Clinical signs and symptoms
Diffuse neurologic symptoms, % (n1/n) 81 (13/16) 100 (9/9) 25 (1/4) 100 (2/2) 100 (1/1)
Encephalopathy 92 (12/13) 100 (9/9) 100 (1/1) 100 (2/2) 100 (1/1)
Behavioral/psychiatric changes 85 (11/13) 100 (9/9) 0 50 (1/2) 100 (1/1)
Cognitive dysfunction 62 (8/13) 67 (6/9) 0 100 (2/2) 100 (1/1)
Focal neurologic symptoms, % (n1/n) 31 (5/16) 11 (1/9) 100 (4/4) 0 0
Facial palsy 20 (1/5) 100 (1/1) 0 — —
Optic neuritis 20 (1/5) 0 50 (2/4) — —
Transverse myelitis 20 (1/5) 0 25 (1/4) — —
Hiccups/vomiting 40 (2/5) 0 50 (2/4) — —
Ataxia 20 (1/5) 0 25 (1/4)
Involuntary movements, % (n1/n) 31 (5/16) 56 (5/9) 0 0 0
Hallucinations, % (n1/n) 25 (4/16) 44 (4/9) 0 0 0
Seizures, % (n1/n) 56 (9/16) 67 (6/9) 0 100 (2/2) 100 (1/1)
Status epilepticus 22 (2/9) 17 (1/6) — 50 (1/2) 0
Inflammatory markers
Serologic inflammatory markers
ESR mm/1h, median (range) 19 (1–65) 14.5 (1–52) 18.5 (1–65) 29.5 (29–30) 2
Increased ESR >10 mm/h, % (n/children tested) 53 (8/15) 50 (4/8) 50 (2/4) 100 (2/2) 0 (0/1)
CRP mg/L, median (range) 1.5 (0.3–65.4) 2.0 (0.6–29.6) 1.3 (0.3–1.3) 41.5 (17.6–65.4) 0.7
Elevated CRP >8 mg/L, % (n/children tested) 20 (3/15) 11 (1/9) 0 (0/3) 100 (2/2) 0 (0/1)
WBC 109/L, median (range) 7.9 (5.8–14.7) 8.5 (7.0–14.7) 7.3 (5.8–8.2) 6.8 (5.7–7.9) 8.1
Leucocytosis >10 3 109/L, % (n/children tested) 19 (3/16) 33 (3/9) 0 (0/4) 0 (0/2) 0 (0/1)
vWF IU/mL, median (range) 1.7 (0.8–4.2) 1.6 (0.8–1.8) 3.1 (1.95–4.2) 2.0 0.73
Abnormal vWF, % (n/children tested) 33 (3/9) 17 (1/6) 100 (2/2) 0 (0/1) 0 (0/1)
CSF inflammatory markers
Cell count 106/L, median (range) 13 (1–80) 24 (2–80) 5 (1–58) 5 (2–7) 7
CSF cell count >5 3 106/L, % (n/children tested) 67 (10/15) 78 (7/9) 66 (2/3) 50 (1/2) 100 (1/1)
Protein g/L, median (range) 0.36 (0.17–1.37) 0.23 (0.17–1.37) 0.18 (0.18–1.26) 0.49 (0.4–0.58) 0.36
CSF protein >0.4 g/L, % (n/children tested) 33 (5/15) 33 (3/9) 33 (1/3) 50 (1/2) 0 (0/1)
Oligoclonal bands positive, % (n/children
tested)
50 (4/8) 60 (3/5) 33 (1/3) ND ND
Neuroimaging at presentation
Abnormal MRI brain, % (n1/n) 44 (7/16) 11 (1/9) 100 (4/4) 50 (1/2) 100 (1/1)
Abnormal MRI spine, % (n/children scanned) 44 (4/9) 0 (0/2) 50 (2/4) 0 (0/1) ND
Abbreviations: CRP 5 C-reactive protein; ESR 5 erythrocyte sedimentation rate; GAD65 5 glutamic acid decarboxylase 65; IBrainD 5 inflammatory brain
diseases; ND 5 not done; vWF 5 von Willebrand factor; WBC 5 white blood cell count.
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(ON, 1 child), and a diencephalic syndrome with
amenorrhea and encephalopathy (1 child). One child
presented with brainstem symptoms that went undi-
agnosed over 2 months until the patient developed
bilateral ON and LETM. None of the children had
seizures or clinical signs suggestive of an underlying
systemic autoimmune disease. All 4 patients demon-
strated focal lesions on brain MRI. Two children also
had spinal cord lesions on presentation; one showed
an LETM extending from C2 to T12/L1 without
enhancement and the other had subtle intramedullary
signal changes at T3/4 and T8/9 without enhance-
ment (table 2). One child required ICU admission
due to clinical deterioration (decreased level of con-
sciousness and inability to secure the airway). Immu-
nosuppressive treatment was started in all patients;
the child requiring ICU admission was treated ac-
cording to the institutional protocol and the remain-
ing 3 were treated with corticosteroids and rituximab
only (2 children) and azathioprine 100 mg PO daily
(1 child). At last clinical encounter after a median
follow-up time of 1.5 years (range 1.0–1.8 years), 3
patients had a good outcome; the child who presented
with ON had a bad outcome according to the PSOM,
remaining blind in one eye (table 3).
Hashimoto encephalitis. Two previously normally
developed female patients, ages 13 and 11 years, pre-
sented with decline in school performance, progress-
ive encephalopathy over a few weeks, and seizures.
Neither patient presented with focal neurologic defi-
cits. Serologic inflammatory markers were mildly ele-
vated (table 2). Inflammatory rheumatologic workup
revealed positive anti-TPO titers of 376 IU/L (,35)
and 6,747 IU/L (,35), respectively, alongside nor-
mal thyroid function (thyroid-stimulating hormone,
T3, and T4). The latter child had been diagnosed
with Hashimoto thyroiditis the year before and was
being treated with levothyroxine 50 mg/day. CSF
inflammatory markers and an extensive infectious
and metabolic workup were noncontributory. Brain
MRI was abnormal in 1 child, showing symmetric
high fluid-attenuated inversion recovery (FLAIR)
and T2 signal with mild enlargement of bilateral
amygdala and hippocampi. The lesions were neither
enhancing nor diffusion-restricted. The 11-year-old
girl required ICU admission due to status epilepticus.
Her initial EEG showed periodic lateralized epilepti-
form discharges (left . right), electroencephalo-
graphic seizures, and diffuse slowing. The EEG of
the 13-year-old girl showed intermittent left frontal
and midline frontal slowing with no epileptiform dis-
charges, and she had a normal brain MRI (table 2).
She recovered spontaneously after 5 days of hospital
admission and did not require further treatment.
The patient in the ICU continued to be encepha-
lopathic despite control of seizure activity with double
antiepileptic medication. She was started on the insti-
tutional immunosuppressive protocol and discharged
Table 3 Outcome of children diagnosed with antibody-associated inflammatory brain diseases at last follow-up
Antibody- associated
IBrainD
Anti–NMDA receptor
encephalitis
Aquaporin-4
autoimmunity
Hashimoto
encephalitis
Anti-GAD65
encephalitis
Death, n (%) 1 (6) 1 (11) 0 0 0
Neurologic function as defined by PSOMa
Good outcome (no functional neurologic
deficit), n (%)
11 (73) 7 (88) 3 (75) 1 (50) 0
Bad outcome (any functional neurologic
deficit), n (%)
4 (27) 1 (12) 1 (25) 1 (50) 1
Deficits according to PSOM
Cranial nerve deficits, n 1 0 1 0 0
Motor deficits, n 0 0 0 0 0
Language deficits, n 1 1 0 0 0
Cognitive/behavior deficits, n 3 1 0 1 1
Residual clinical seizures, n (%)b 2 (22) 0 N/A 1 (50) 1
On antiepileptic medication, n (%) 3 (33) 1 (13) — 1 (50) 1
Participation
Children attending school, n (%) 14 (93) 8 (100) 4 (100) 2 (100) 0
IEP or other support required, n (%) 5 (36) 3 (38) 1 (25) 1 (50) —
Abbreviations: GAD65 5 glutamic acid decarboxylase 65; IBrainD 5 inflammatory brain diseases; IEP 5 individualized education program; PSOM 5
Pediatric Stroke Outcome Measure.
a The child with anti–NMDA receptor encephalitis who died was excluded from further outcome assessment.
bOnly referring to those 9 patients who presented with seizures at disease onset.
Neurology: Neuroimmunology & Neuroinflammation 5
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
into a rehabilitation facility where she continued to
improve slowly. After a follow-up time of 2.2 years,
she had a normalized anti-TPO titer and an absence
of focal neurologic deficits but continued to have seiz-
ures several times a month. As a result, she also expe-
rienced marked cognitive sequelae that required a
modified educational curriculum (table 3). Her last
brain MRI, performed 2 years after disease onset,
revealed bilateral hippocampal volume loss.
Anti- GAD65 encephalitis. A 15-year-old previously
healthy boy presented with a self-limited
(,5 minutes) generalized tonic-clonic seizure. He
reported 8–9 months of moderately severe nonthrob-
bing headaches occurring several times per week,
1 month of amnestic events, and 1 week of leg twitch-
ing occurring 2–3 times/day. No focal neurologic
deficits were noted on examination. Laboratory inves-
tigations, including complete blood count, CRP,
ESR, electrolytes, kidney and liver function tests, thy-
roid function anti-TPO antibodies, and anti–NMDA
receptor antibodies, were normal. CSF analysis was
remarkable for 7 white blood cells, normal glucose,
and normal protein (table 2). CSF cytopathology and
encephalitis workup was unremarkable. EEG demon-
strated asymmetrical slowing of the background
rhythm in the left hemisphere with epileptiform
activity. Brain MRI revealed abnormal high T2 and
FLAIR signal in the right hippocampus associated
with mild swelling and bilateral signal abnormality
in the amygdalae without enhancement. The patient
was started on levetiracetam 500 mg BID and dis-
charged after no further seizures occurred. Three
months later, he presented with an increased fre-
quency of focal seizures (one seizure every 3 hours).
Seizure semiology was significant for nonsuppressible
left leg twitching. Daily episodes of confusion lasting
30–60 minutes, a decline in school performance, a
subjective sensation of “mental fog,” and decreased
memory function were also reported. On readmis-
sion, no psychiatric disturbances, focal neurologic
deficits, or dyskinesia were noted on examination.
Montreal Cognitive Assessment score was normal
(30/30); however; he demonstrated significant diffi-
culties in recalling events that occurred earlier the
same day. Brain MRI was unchanged compared to
prior studies. Twenty-four-hour EEG recording cap-
tured a total of 6 ictal episodes (3 originating from the
right hemisphere and 3 from the left hemisphere).
Repeat CSF analysis demonstrated 9 white blood
cells, normal glucose and protein, and positive oligo-
clonal banding. The combination of EEG and neuro-
imaging findings prompted the diagnosis of limbic
encephalitis. Levetiracetam was increased to 1,500
mg BID. Further analyses of antineuronal (intracel-
lular and extracellular) antibodies demonstrated the
presence of anti-GAD65 antibodies in both serum
and CSF. The patient was started on the institutional
treatment protocol for AB-associated IBrainD (see
figures e-1 and e-2). At last follow-up, 2.4 years after
diagnosis, the patient was still having focal seizures
several times per week. At that time, he was unable to
attend school and reported significant memory loss
and moodiness (table 3). The last brain MRI, per-
formed approximately 2 years after diagnosis, showed
right hippocampal volume loss with mild T2 and
FLAIR hyperintensity in both amygdalae.
DISCUSSION In this study, we systematically
described the clinical spectrum of AB-associated
IBrainD in children. AB-associated IBrainD comprise
approximately 10% of all pediatric IBrainD. The
spectrum of AB-associated IBrainD is rapidly evolving
due to an increasing ability to detect autoantibodies
(figure 2). Children present with a wide range of
symptoms, including encephalopathy, seizures,
involuntary movements, and various focal neurologic
deficits. The clinical heterogeneity has a significant
impact on the time to diagnosis, which was
approximately 2 months in our study. AB-associated
IBrainD have devastating consequences for patients
and families, as they led to function-limiting
neurologic sequelae in one-fourth of our study
population. Delays in diagnosis have been shown to
be associated with further adverse outcomes.13–15
However, specific antibody testing and targeted
treatment approaches are now available. As a result, it
is of clinical importance to increase the awareness of the
distinct pediatric AB-associated IBrainD phenotypes in
order to shorten the time from symptom onset to
diagnosis and to ensure timely initiation of treatment.
The clinical spectrum of AB-associated IBrainD is
heterogeneous. The study revealed a dichotomous
division of the 2 major clinical phenotypes: the first,
comprised of encephalopathy and seizures, is often
seen alongside an unremarkable MRI and/or an
MRI with lesions secondary to prolonged seizure
activity, and the second involves focal neurologic def-
icits accompanied by a characteristically abnormal
MRI. In this study, anti–NMDA receptor encepha-
litis, anti-GAD65 encephalitis, and Hashimoto
encephalopathy belonged to the first category,
whereas AQP4 autoimmunity belonged to the sec-
ond. Considering the pathophysiologic mechanisms
of the antibodies, this seems biologically plausible for
both anti–NMDA receptor encephalitis and anti-
GAD65 encephalitis, whereas the pathophysiologic
mechanism involved in Hashimoto encephalopathy
remains unknown. Anti–NMDA receptor antibodies
lead to internalization and a subsequent reduction in
the number of NMDA receptors on the cell surface.
This ultimately results in a characteristic clinical phe-
notype that includes behavioral, learning, and
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memory dysfunction as well as encephalopathy and
seizures, all in the context of a seemingly normal MRI
or an MRI with changes attributed to prolonged sei-
zure activity only.16–18 Similarly, in anti-GAD65
encephalitis, the antibody is thought to interfere with
GABA metabolism, leading to increased seizure activ-
ity.19–21 However, while the pathogenetic mechanism
in anti–NMDA receptor encephalitis has been well-
established, the role of the anti-GAD65 antibody is
not fully understood yet. In contrast, the NMO-IgG
binds to the AQP4 channel on the foot processes of
astrocytes, leading to an acute and often destructive
inflammatory process that can be seen on MRI in
AQP4-dense areas of the brain, such as the area post-
rema or the diencephalon.9,22–26 This explains the
clinical presentation of pediatric patients with
AQP4 autoimmunity. Upon presentation, they fre-
quently show symptoms other than ON or transverse
myelitis but with a clear localization to AQP4 dense
areas. These symptoms have been previously
described and include intractable hiccups/vomiting,
encephalopathy, endocrinopathies, and menstrual
irregularities.2,27,28 Hence, AB-associated IBrainD
remain an important differential diagnosis not only
among IBrainD but also within the broader field of
pediatric neurology.
Unique to AB-associated IBrainD is the availabil-
ity of a biomarker that is the antibody itself. Serologic
and CSF inflammatory markers are rather unspecific;
however, antibody testing facilitates a specific diagno-
sis. In contrast, other IBrainD lack specific bio-
markers and rely heavily on invasive tests. For
example, in patients with suspected CNS vasculitis,
conventional angiography (large vessel vasculitis) or
even brain biopsy (small vessel vasculitis) is required
to establish the diagnosis.29–34
Rapid, comprehensive testing using serum and
CSF is needed to avoid delays in diagnosis. Overall,
CSF testing appears to be more sensitive and specific.
Two patients (12.5%)—1 with anti–NMDA recep-
tor encephalitis and 1 with AQP4 autoimmunity—
had positive antibody testing in CSF only, while the
sera remained negative. A recent study analyzing 250
patients with anti–NMDA receptor encephalitis
demonstrated that CSF antibody testing had a higher
sensitivity than serum antibody testing (100% vs
85.6%, p , 0.0001).35 Other authors have also indi-
cated that serum has a lower sensitivity and specificity
than CSF for NMDA receptor antibody determina-
tion; in addition, the disorder is characterized by
intrathecal antibody synthesis.11,36,37 Therefore, in pa-
tients with anti–NMDA receptor encephalitis, anti-
body testing in serum alone carries the risk of missing
or delaying the diagnosis in a potentially devastating
but treatable neurologic disease. In contrast, in pa-
tients with AQP4 autoimmunity, the role of CSF
antibody testing remains controversial, and intrathe-
cal synthesis of AQP4 antibody is questionable.38–41
However, our study and the literature report AQP4
antibody in CSF in seronegative patients. Since early
and targeted treatment initiation is key in preventing
relapses and permanent disability, CSF AQP4 anti-
body testing may need to be considered in patients
with a high clinical suspicion of AQP4 autoimmunity
despite seronegativity. It is also important to consider
the type of assay used. Although there is a high
Figure 2 Cumulative enrollment of antibody-associated inflammatory brain diseases during the study period
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specificity for AQP4 antibody among various immu-
nologic techniques, cell-based assays seem to be more
sensitive than tissue- or protein-based assays.42
The limitations of this study are inherent to its ret-
rospective design. First, selection bias should be
noted, given that The Hospital for Sick Children is
a tertiary care center that receives referrals for sicker
patients. Second, since recognition of antibody-
associated conditions is growing, an underestimation
of the number of AB-associated IBrainD earlier in the
study period is likely. Finally, the small size of the Ha-
shimoto encephalitis and anti-GAD65 encephalitis
groups does not guarantee external validity.
An increasing number of children have been diag-
nosed with AB-associated IBrainD over the past
decade. One-fourth of our patients were left with
function-limiting sequelae. The devastating potential
of these conditions underscores the need for increased
awareness and understanding of their clinical presen-
tation. This in turn will facilitate faster comprehen-
sive antibody testing, ultimately leading to more
timely treatment for children. As shown in our study,
antibody-associated diseases are an evolving spec-
trum. More advanced immunohistochemical techni-
ques are likely to discover more antibodies involved
in the pathogenesis of neurologic conditions currently
considered of “unknown origin.” Beyond the
antibody-associated diseases presented in this study,
antibodies may also play a role in the symptom evo-
lution of neurologic diseases otherwise considered
static. It is possible that a lesion might function as a
trigger for an antibody-mediated or antibody-
associated inflammatory reaction, conceptually lead-
ing to secondary AB-associated IBrainD. Therefore,
larger multicenter prospective studies are required in
order to better understand the heterogeneous nature
of AB-associated IBrainD and to compare different
immunosuppressive treatment strategies.
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